Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.

Marc F. Pelletier, PhD - President & CEO

Dr. Pelletier co-founded Aeromics at Yale School of Medicine with Dr. Walter Boron, and has been CEO/CSO since its founding in 2008. Dr. Pelletier built the company from the ground up and oversees strategic and scientific operations. He initiated Aeromics’ drug discovery program which produced inhibitors of aquaporins for the treatment of cerebral edema and has over 22 years of experience in the life sciences. Dr. Pelletier also holds an Adjunct Professor position in the Department of Physiology and Biophysics at Case Western Reserve University. 

Paul R. McGuirk, PhD - Vice President Medicinal Chemistry and Clinical Development

Dr. McGuirk guides our medicinal chemistry and clinical development strategies. He has over 27 years of experience in drug discovery and development. As an Executive Director at Pfizer Inc. (retired) he was responsible for several therapeutic areas and technology programs that progressed from the initial screening stages all the way up through the clinic including two marketed drugs. During that time he was one of the key leaders in charge of building a 3 million compound chemical library and integrating ADME/tox HTS into all medicinal chemistry programs. Dr. McGuirk is an inventor on 15 U.S. patents.  

George W. Farr, PhD - Vice President Pharmacology

Dr. Farr participates at all levels of research conducted by Aeromics. His primary responsibilities include direction of our biochemical and biophysical research as well as pharmacological proof of concept studies. Beginning at Case Western Reserve University School of Medicine and more recently at Yale School of Medicine as an HHMI scientist he has been at the cutting edge of biomedical science for over 20 years. With a broad range of experience encompassing biochemistry, biophysics, cell and molecular biology, pharmacolgy and animal studies Dr. Farr brings a unique skill set to the Aeromics team.

James P. Linton, PhD, MBA - Strategic Business Advisor

With over 25 years of experience as a biotech executive/entrepreneur co-founding six biotechnology companies and has successfully exited multiple companies including Protometrix, Genicon, and Owl Biomedical. Dr. Linton overseas business strategy and development.